Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first time • VYJUVEK received Orphan Drug Designation and PRIME designation from the EMA PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- (the "Company") KRYS, a…#deb #vyjuvek #ema #pittsburgh #krys #maa #sumakrishnan #researchdevelopment #krystalbiotech #epidermolysisbullosa (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2023 Category: Consumer Health News Source Type: news
Oleogel-S10 Reduces Daily Dressing Need in EB Study Oleogel-S10 Reduces Daily Dressing Need in EB Study
Oleogel-S10 reduced the need for daily dressing changes compared with a control gel in patients with epidermolysis bullosa, according to a further analysis of data from the phase 3 EASE study.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 24, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 26, 2023 Category: Drugs & Pharmacology Source Type: news
Breakthrough In Gene Therapy: Epidermolysis Bullosa
In a groundbreaking development, gene therapy delivered through eyedrops has restored the sight of a teenager who has been legally blind for most of his life. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 17, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Camp for Kids With Skin Disorders Marks 30th Anniversary Camp for Kids With Skin Disorders Marks 30th Anniversary
The camp, sponsored by the American Academy of Dermatology, accepts youth with conditions ranging from eczema and psoriasis to vitiligo, alopecia, epidermolysis bullosa, and ichthyosis.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 25, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Progress Seen in Substantially Improving Treatment of EB Progress Seen in Substantially Improving Treatment of EB
The promise of gene, cell, and protein therapies for epidermolysis bullosa has been pursued for years, but accelerated progress is translating into new therapies now available or in phase 3 trials.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 24, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
First Ever Topical Gene Therapy Approved For “Butterfly Disease” Children
Topical gene therapy VYJUVEK approved Butterfly Disease Epidermolysis Bullosa Beremagene Geperpavec (B-VEC) EBRP (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 24, 2023 Category: Pharmaceuticals Authors: Greg Licholai, MD, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news
U.S. FDA approves Krystal Biotech's skin-disorder gene therapy
The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's (KRYS.O) first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in afternoon trading. Patients with the rare dystrophic epidermolysis bullosa disorder suffer from open…#krystalbiotechinc #vyjuvek #krystalbiotech #krishkrishnan #fda #krishnan #krystal #bengaluru (Source: Reuters: Health)
Source: Reuters: Health - May 20, 2023 Category: Consumer Health News Source Type: news
Krystal Biotech receives FDA approval for innovative gene therapy drug
Krystal Biotech Inc. announced that the U.S. Food and Drug Administration approved the use of VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) for patients who are six months of age or older. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 19, 2023 Category: American Health Authors: Nate Doughty Source Type: news
FDA Approves First-Ever Topical Gene Therapy FDA Approves First-Ever Topical Gene Therapy
The topical treatment will be used to treat wounds in patients with dystrophic epidermolysis bullosa.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 19, 2023 Category: Drugs & Pharmacology Tags: Dermatology News Alert Source Type: news
Rare Skin Blistering Condition Gets First Drug Approved
(MedPage Today) -- Credit: B.E.L.A. butterfly children
The FDA granted the first drug approval for dystrophic epidermolysis bullosa (DEB), a topical gene therapy that treats the blistering wounds it causes, the agency announced Friday.
The... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 19, 2023 Category: American Health Source Type: news
FDA Approves Vyjuvek (beremagene geperpavec-svdt) Redosable Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, May 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the US Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 19, 2023 Category: Drugs & Pharmacology Source Type: news
Topical Gene Therapy Gel Heals Dystrophic EB Wounds Topical Gene Therapy Gel Heals Dystrophic EB Wounds
The first topical in vivo gene therapy to reach late-stage development heals dystrophic epidermolysis bullosa wounds, researchers report.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 26, 2023 Category: Drugs & Pharmacology Tags: Dermatology News Source Type: news
Topical Gene Therapy Heals Blistering Skin Disease Lesions
(MedPage Today) -- A novel topical gene therapy healed most lesions among patients with dystrophic epidermolysis bullosa, a rare genetic blistering skin disease, the GEM-3 trial showed.
Topical administration of beremagene geperpavec (B-VEC) led... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - December 14, 2022 Category: Dermatology Source Type: news
Topical Gel for Epidermolysis Bullosa Shows Ongoing Benefit Topical Gel for Epidermolysis Bullosa Shows Ongoing Benefit
Patients with EB experienced substantial reductions in affected skin area with continued use of the bark-derived topical agent oleogel-S10 in an open-label extension study.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 12, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
